Cargando…
(18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI
OBJECTIVE: To compare the presence of post-operative residual disease by magnetic resonance imaging (MRI) and [18F]fluorothymidine (FLT)-positron emission tomography (PET)-computer tomography (CT) in patients with malignant glioma and to estimate the impact of (18)F-FLT PET on the delineation of pos...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349865/ https://www.ncbi.nlm.nih.gov/pubmed/25738617 http://dx.doi.org/10.1371/journal.pone.0118769 |
_version_ | 1782360097695989760 |
---|---|
author | Zhao, Fen Li, Minghuan Wang, Zhiheng Fu, Zheng Cui, Yunfeng Chen, Zhaoqiu Yu, Jinming |
author_facet | Zhao, Fen Li, Minghuan Wang, Zhiheng Fu, Zheng Cui, Yunfeng Chen, Zhaoqiu Yu, Jinming |
author_sort | Zhao, Fen |
collection | PubMed |
description | OBJECTIVE: To compare the presence of post-operative residual disease by magnetic resonance imaging (MRI) and [18F]fluorothymidine (FLT)-positron emission tomography (PET)-computer tomography (CT) in patients with malignant glioma and to estimate the impact of (18)F-FLT PET on the delineation of post-operative target volumes for radiotherapy (RT) planning. METHODS: Nineteen patients with post-operative residual malignant gliomas were enrolled in this study. For each patient, (18)F- FLT PET-CT and MRI were acquired in the same week, within 4 weeks after surgery but before the initiation of RT. The PET-CT and MRI data were co-registered based on mutual information. The residual tumor volume defined on the (18)F-FLT PET (Vol-PET) was compared with that of gadolinium [Gd] enhancement on T1-weighted MRI (Vol-T1) and areas of hyperintensity on T2-weighted MRI (Vol-T2). RESULTS: The mean Vol-PET (14.61 cm(3)) and Vol-T1 (13.60 cm(3)) were comparable and smaller than the mean Vol-T2 (32.93 cm(3)). The regions of (18)F-FLT uptake exceeded the contrast enhancement and the hyperintense area on the MRI in 14 (73.68%) and 8 patients (42.11%), respectively. In 5 (26.32%) of the 19 patients, Vol-PET extended beyond 25 mm from the margin of Vol-T1; in 2 (10.53%) patients, Vol-PET extended 20 mm from the margin of Vol-T2. Vol-PET was detected up to 35 mm away from the edge of Vol-T1 and 24 mm away from the edge of Vol-T2. In 16 (84.21%) of the 19 patients, the Vol-T1 extended beyond the Vol-PET. In all of the patients, at least some of the Vol-T2 was located outside of the Vol-PET. CONCLUSIONS: The volumes of post-operative residual tumor in patients with malignant glioma defined by (18)F-FLT uptake on PET are not always consistent with the abnormalities shown on post-operative MRI. Incorporation of (18)F-FLT-PET in tumor delineation may have the potential to improve the definition of target volume in post-operative radiotherapy. |
format | Online Article Text |
id | pubmed-4349865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-43498652015-03-17 (18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI Zhao, Fen Li, Minghuan Wang, Zhiheng Fu, Zheng Cui, Yunfeng Chen, Zhaoqiu Yu, Jinming PLoS One Research Article OBJECTIVE: To compare the presence of post-operative residual disease by magnetic resonance imaging (MRI) and [18F]fluorothymidine (FLT)-positron emission tomography (PET)-computer tomography (CT) in patients with malignant glioma and to estimate the impact of (18)F-FLT PET on the delineation of post-operative target volumes for radiotherapy (RT) planning. METHODS: Nineteen patients with post-operative residual malignant gliomas were enrolled in this study. For each patient, (18)F- FLT PET-CT and MRI were acquired in the same week, within 4 weeks after surgery but before the initiation of RT. The PET-CT and MRI data were co-registered based on mutual information. The residual tumor volume defined on the (18)F-FLT PET (Vol-PET) was compared with that of gadolinium [Gd] enhancement on T1-weighted MRI (Vol-T1) and areas of hyperintensity on T2-weighted MRI (Vol-T2). RESULTS: The mean Vol-PET (14.61 cm(3)) and Vol-T1 (13.60 cm(3)) were comparable and smaller than the mean Vol-T2 (32.93 cm(3)). The regions of (18)F-FLT uptake exceeded the contrast enhancement and the hyperintense area on the MRI in 14 (73.68%) and 8 patients (42.11%), respectively. In 5 (26.32%) of the 19 patients, Vol-PET extended beyond 25 mm from the margin of Vol-T1; in 2 (10.53%) patients, Vol-PET extended 20 mm from the margin of Vol-T2. Vol-PET was detected up to 35 mm away from the edge of Vol-T1 and 24 mm away from the edge of Vol-T2. In 16 (84.21%) of the 19 patients, the Vol-T1 extended beyond the Vol-PET. In all of the patients, at least some of the Vol-T2 was located outside of the Vol-PET. CONCLUSIONS: The volumes of post-operative residual tumor in patients with malignant glioma defined by (18)F-FLT uptake on PET are not always consistent with the abnormalities shown on post-operative MRI. Incorporation of (18)F-FLT-PET in tumor delineation may have the potential to improve the definition of target volume in post-operative radiotherapy. Public Library of Science 2015-03-04 /pmc/articles/PMC4349865/ /pubmed/25738617 http://dx.doi.org/10.1371/journal.pone.0118769 Text en © 2015 Zhao et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zhao, Fen Li, Minghuan Wang, Zhiheng Fu, Zheng Cui, Yunfeng Chen, Zhaoqiu Yu, Jinming (18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI |
title |
(18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI |
title_full |
(18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI |
title_fullStr |
(18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI |
title_full_unstemmed |
(18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI |
title_short |
(18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI |
title_sort | (18)f-fluorothymidine pet-ct for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with mri |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349865/ https://www.ncbi.nlm.nih.gov/pubmed/25738617 http://dx.doi.org/10.1371/journal.pone.0118769 |
work_keys_str_mv | AT zhaofen 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri AT liminghuan 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri AT wangzhiheng 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri AT fuzheng 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri AT cuiyunfeng 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri AT chenzhaoqiu 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri AT yujinming 18ffluorothymidinepetctforresectedmalignantgliomasbeforeradiotherapytumorextentaccordingtoproliferativeactivitycomparedwithmri |